Adverse reactions of Axitinib

Because clinical trials are conducted under widely varying conditions, adverse reaction rates  observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of  another drug and may not reflect the rates observed in clinical practice.

The safety of Axitinib has been evaluated in 715 patients in monotherapy studies, which  included 537 patients with advanced RCC. The data described  reflect exposure to Axitinib in 359 patients with advanced RCC who participated in a  randomized clinical study versus sorafenib.

The following risks, including appropriate action to be taken, are discussed in greater detail in  other sections of the label: hypertension,  arterial thromboembolic events, venous thromboembolic events, hemorrhage, gastrointestinal  perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS,  proteinuria, elevation of liver enzymes, and fetal development.

FDA，2012.01